Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- 1 February 2019
- journal article
- review article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 30 (2), 219-235
- https://doi.org/10.1093/annonc/mdy551
Abstract
Background: Cancer immunotherapy has changed the standard of care for a subgroup of patients with advanced disease. Immune checkpoint blockade (ICB) in particular has shown improved survival compared with previous standards of care for several tumor types. Although proven to be successful in more immunogenic tumors, ICB is still largely ineffective in patients with tumors that are not infiltrated by immune cells, the so- called cold tumors. Patients and methods: This review describes the effects of different chemotherapeutic agents on the immune system and the potential value of these different types of chemotherapy as combination partners with ICB in patients with solid tumors. Both preclinical data and currently ongoing clinical trials were evaluated. In addition, we reviewed findings regarding different dosing schedules, including the effects of an induction phase and applying metronomic doses of chemotherapy. Results: Combining ICB with other treatment modalities may lead to improved immunological conditions in the tumor microenvironment and could thereby enhance the antitumor immune response, even in tumor types that are so far unresponsive to ICB monotherapy. Chemotherapy, that was originally thought to be solely immunosuppressive, can exert immunomodulatory effects which may be beneficial in combination with immunotherapy. Each chemotherapeutic drug impacts the tumor microenvironment differently, and in order to determine the most suitable combination partners for ICB it is crucial to understand these mechanisms. Conclusion: Preclinical studies demonstrate that the majority of chemotherapeutic drugs has been shown to exert immunostimulatory effects, either by inhibiting immunosuppressive cells and/ or activating effector cells, or by increasing immunogenicity and increasing T- cell infiltration. However, for certain chemotherapeutic agents timing, dose and sequence of administration of chemotherapeutic agents and ICB is important. Further studies should focus on determining the optimal drug combinations, sequence effects and optimal concentration- time profiles in representative preclinical models.Keywords
This publication has 135 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor ImmunityPLOS ONE, 2013
- The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cuesCancer Immunology, Immunotherapy, 2011
- Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cellsCancer Immunology, Immunotherapy, 2010
- Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stagesVaccine, 2009
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesBritish Journal of Cancer, 2009
- Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell MaturationCancer Research, 2009
- Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytesClinical and Experimental Immunology, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma modelCancer Immunology, Immunotherapy, 2002